Dr. Becker joined Vidac Pharmaceuticals as President and Chief Executive Officer in 2013. Dr. Becker brings more than 20 years of biopharmaceutical industry entrepreneurship and leadership experience to Vidac, with expertise in the discovery and development of innovative novel pharmaceuticals. Dr. Becker led or co-led more than $2B worth of deals with GSK, Amgen, Teva, Clevexel, and CFFT. Dr. Becker was a founder, Director and Chief Science Officer of Predix Pharmaceuticals (Lexington, MA and Ramat-Gan, Israel), a GPCR-focused neurology play, which was acquired by Epix Pharmaceuticals (NASDAQ:EPIX). Subsequently he served as the CSO of Epix. Under his leadership 5 novel drugs were discovered and introduced into clinical development (Phases 1 to 3). Dr. Becker was also the founder, Director and Chief Executive Officer of Dynamix Pharmaceuticals, a cancer and autoimmune drug discovery and development company, and is a co-founder and a member of the Board of Directors of Immunity Pharma, which is developing a novel drug for ALS. Dr. Becker was a professor at Tel-Aviv University and at Harvard University. He holds a PhD from the Hebrew University of Jerusalem, and a post-doctoral training from Harvard University. Dr. Becker has published more than 50 scientific papers, has co-edited two books, and is an inventor on numerous patents.
Prior to joining ViDAC Pharma in late 2012, Dr. Behar served as the Vice President of Biology at Dynamix Pharmaceuticals, a private pharmaceutical company focused on the discovery and development of novel, targeted, small molecule drugs for cancer and auto-immune therapies. In that capacity, Dr. Behar led all biological and pharmacological aspects of the company’s drug pipeline including target selection, and all pre-clinical development. Prior to Dynamix, Dr. Behar worked with Third Rock Ventures as a technology scout, and before that as the Chief Scientist at Quantomix. Dr. Behar also served as a research scientist at Pfizer in Cambridge, MA. Dr. Behar earned her PhD in Molecular Pharmacology from the Division of Medical Sciences at Harvard University where she was awarded the prestigious Ryan Fellowship, and her BSc and MSc and MBA from the Hebrew University in Jerusalem.
Dr. Brickman joined Vidac in 2014 and brings to Vidac more than 35 years of experience in medical practice, laboratory and clinical research, drug development, clinical operations, safety monitoring and regulatory experience. Chaim received his medical degree from the Albert Einstein Medical Center, internal medicine certification at Wayne State University Medical Center, and fellowship training at the National Institute of Allergy and Infectious Diseases (NIAID, NIH). After holding teaching, research, and leadership roles at the NIH, Uniformed Services Medical Center (Maryland), Wayne State University Medical Center, Sinai Hospital of Detroit’s Research Institute, and Wolfson Medical Center (Israel), Chaim held senior positions at Inotek Pharmaceuticals Corporation (USA) and Teva Pharmaceuticals (Israel) where he helped manage Phase I-III clinical trials in the US, Israel, Western Europe, Australia, India, and Eastern Europe. In addition, Dr. Brickman has chaired an Institutional Review Board in the United States and served as medical monitor for numerous international pharmaceutical companies and Contract Research Organizations.
Dr. Salama received his Ph.D. in Organic Chemistry from the University of Montreal (Canada) after completion of a M.Sc. in Chemical Engineering and a B.Sc. in Chemistry from University of Lyon (France). Dr. Salama started his career as a professor at University of Moncton (Canada) where his research focused on the CNS and new organic reaction mechanisms. He then moved to the pharmaceutical industry where he held R&D positions in GMP process chemistry of APIs as well as novel formulations development. Among others, he was Director of Manufacturing at Inotek (Israel) and Vice President of CMC at Chiasma (Israel).